Preliminary Study of Contrast-enhanced Ultrasound in Combination with Blue Dye Vs. Indocyanine Green Fluorescence, in Combination with Blue Dye for Sentinel Lymph Node Biopsy in Breast Cancer
Overview
Authors
Affiliations
Background: This preliminary study aimed to examine the feasibility of sentinel lymph node biopsy (SLNB) using contrast-enhanced ultrasound (CEUS) vs. indocyanine green fluorescence (ICG), combined with blue dye in patients with breast cancer.
Methods: This was a retrospective study of consecutive female patients with invasive stage I-III (based on pre-operative physical examination and imaging) primary breast cancer at the Peking Union Medical College Hospital between 01/2013 and 01/2015 who underwent preoperative SLNB by ICG + blue dye or CEUS + blue dye. The numbers of detected SLNs, detection rates, and recurrence-free survival (RFS) rates were compared between the two groups.
Results: A total of 443 patients were included. The detection rates of SLNs in the CEUS + blue dye and ICG + blue dye groups were 98.4 and 98.1%, respectively (P = 0.814). The average numbers of SLNs detected per patient showed no significant difference between the two groups (3.06 ± 1.33 and 3.12 ± 1.31 in the CEUS + blue dye and ICG + blue dye groups, respectively; P = 0.659). After a median follow-up of 46 months, five patients in the CEUS + blue dye group and 15 in the ICG + blue dye group had recurrence. RFS rates showed no significant difference (P = 0.55).
Conclusion: This preliminary study suggests that CEUS + blue dye and ICG + blue dye are both feasible for SLN detection in breast cancer.
Determining Accurate Dye Combinations for Sentinel Lymph Node Detection: A Systematic Review.
Swerdlow M, Vangsness K, Kress G, Georgescu A, Wong A, Carre A Plast Reconstr Surg Glob Open. 2024; 12(2):e5598.
PMID: 38333031 PMC: 10852373. DOI: 10.1097/GOX.0000000000005598.
Zhang C, Zhang Y, Liang M, Shi X, Jun Y, Fan L Front Immunol. 2022; 13:1063678.
PMID: 36532036 PMC: 9751193. DOI: 10.3389/fimmu.2022.1063678.
Li J, Li H, Guan L, Lu Y, Zhan W, Dong Y BMC Cancer. 2022; 22(1):455.
PMID: 35473499 PMC: 9040273. DOI: 10.1186/s12885-022-09551-y.
Liu H, Sun M, Liu L, Yu Z, Chen X, Liu Q Transl Cancer Res. 2022; 10(12):5222-5237.
PMID: 35116372 PMC: 8798807. DOI: 10.21037/tcr-21-1239.
Zhu Y, Fan X, Yang D, Dong T, Jia Y, Nie F Diagnostics (Basel). 2021; 11(11).
PMID: 34829452 PMC: 8624576. DOI: 10.3390/diagnostics11112104.